Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 23;16(17):2931.
doi: 10.3390/cancers16172931.

Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma

Deevyashali S Parekh  1 , Yun Kyoung Ryu Tiger  2 , Kevin Tony Jamouss  3 , Justin Hassani  3 , Maroun Bou Zerdan  1 , Shahzad Raza  4
Affiliations
Review

Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma

Deevyashali S Parekh et al. Cancers (Basel). .

Abstract

Multiple myeloma is a heterogeneous condition characterized by the proliferation of monoclonal B-cells, for which there is currently no curative treatment available. Relapses are, unfortunately, common after first-line treatment. While the prognosis for relapsed refractory multiple myeloma is generally poor, advances in the treatment of relapsed or refractory multiple myeloma offer hope. However, the expansion of effective options in targeted treatment offers renewed optimism and hope that patients who fail on older therapies may respond to newer modalities, which are often used in combination. We review currently approved and novel investigational agents classified by mechanisms of action, efficacy, approved setting, and adverse events. We delve into future directions of treatment for relapsed/refractory multiple myeloma, reviewing novel agents and therapeutic targets for the future.

Keywords: CAR-T; bispecific antibodies; celmods; monoclonal antibodies; multiple myeloma; proteasome inhibitors; relapsed refractory.

PubMed Disclaimer

Conflict of interest statement

Shahzad Raza-Advisory board Prothena, Pfizer. The other authors declare no conflict of interest.

References

    1. Stewart A.K., Rajkumar S.V., Dimopoulos M.A., Masszi T., Špička I., Oriol A., Hájek R., Rosiñol L., Siegel D.S., Mihaylov G.G., et al. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. N. Engl. J. Med. 2015;372:142–152. doi: 10.1056/NEJMoa1411321. - DOI - PubMed
    1. Moreau P., Masszi T., Grzasko N., Bahlis N.J., Hansson M., Pour L., Sandhu I., Ganly P., Baker B.W., Jackson S.R., et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N. Engl. J. Med. 2016;374:1621–1634. doi: 10.1056/NEJMoa1516282. - DOI - PubMed
    1. Richardson P.G., Kumar S.K., Masszi T., Grzasko N., Bahlis N.J., Hansson M., Pour L., Sandhu I., Ganly P., Baker B.W., et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J. Clin. Oncol. 2021;39:2430–2442. doi: 10.1200/JCO.21.00972. - DOI - PubMed
    1. Dimopoulos M.A., Goldschmidt H., Niesvizky R., Joshua D., Chng W.-J., Oriol A., Orlowski R.Z., Ludwig H., Facon T., Hajek R., et al. Carfilzomib or Bortezomib in Relapsed or Refractory Multiple Myeloma (ENDEAVOR): An Interim Overall Survival Analysis of an Open-Label, Randomised, Phase 3 Trial. Lancet Oncol. 2017;18:1327–1337. doi: 10.1016/S1470-2045(17)30578-8. - DOI - PubMed
    1. Richardson P.G., Oriol A., Beksac M., Liberati A.M., Galli M., Schjesvold F., Lindsay J., Weisel K., White D., Facon T., et al. Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with Lenalidomide (OPTIMISMM): A Randomised, Open-Label, Phase 3 Trial. Lancet Oncol. 2019;20:781–794. doi: 10.1016/S1470-2045(19)30152-4. - DOI - PubMed

LinkOut - more resources